Trials / Withdrawn
WithdrawnNCT03841747
Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Paclitaxel Weekly in ER-positive, Luminal B Metastatic Breast Cancer
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Queen Mary University of London · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PELICAN is a randomised phase II trial that aims to evaluate the efficacy and safety of paclitaxel plus pembrolizumab relative to paclitaxel alone, in patients with locally advanced or metastatic ER-positive, HER2-negative, Luminal B breast cancer who have received no prior chemotherapy for advanced or metastatic disease. Patients will be randomised (2:1) to one of the two treatment arms: * Pembrolizumab plus Paclitaxel * Paclitaxel
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 200 mg Pembrolizumab IV Q3W. |
| DRUG | Paclitaxel | 80 mg/m2 paclitaxel IV on Days 1,8, and 15 of each 28 day cycle. |
Timeline
- Start date
- 2020-12-01
- Primary completion
- 2023-06-01
- Completion
- 2025-06-01
- First posted
- 2019-02-15
- Last updated
- 2024-03-12
Source: ClinicalTrials.gov record NCT03841747. Inclusion in this directory is not an endorsement.